Cargando…

Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial

BACKGROUND/OBJECTIVES: To assess the safety and efficacy of avacincaptad pegol (ACP), a C5 inhibitor, for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) over an 18-month treatment course. SUBJECTS/METHODS: This study was an international, prospective, randomized, double-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Sunil S., Lally, David R., Hsu, Jason, Wykoff, Charles C., Eichenbaum, David, Heier, Jeffrey S., Jaffe, Glenn J., Westby, Keith, Desai, Dhaval, Zhu, Liansheng, Khanani, Arshad M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10686386/ https://www.ncbi.nlm.nih.gov/pubmed/36964259 http://dx.doi.org/10.1038/s41433-023-02497-w

Ejemplares similares

Correction: Avacincaptad pegol for geographic atrophy secondary to age-related macular degeneration: 18-month findings from the GATHER1 trial
por: Patel, Sunil S., et al.
Publicado: (2023)

Emerging Treatment Options for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
por: Khan, Hannah, et al.
Publicado: (2023)

Gradeability and Reproducibility of Geographic Atrophy Measurement in GATHER-1, a Phase II/III Randomized Interventional Trial
por: Li, Angela S., et al.
Publicado: (2023)

OPTIMAL MANAGEMENT OF PIGMENT EPITHELIAL DETACHMENTS IN EYES WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Khanani, Arshad M., et al.
Publicado: (2018)

Complement cascade inhibition in geographic atrophy: a review
por: Desai, Dhaval, et al.
Publicado: (2022)

Phase 1 Dose-Escalation Study of Plasma Kallikrein Inhibitor THR-149 for the Treatment of Diabetic Macular Edema
por: Dugel, Pravin U., et al.
Publicado: (2021)

Impact of Modifying Abicipar Manufacturing Process in Patients with Neovascular Age-Related Macular Degeneration: MAPLE Study Results
por: Callanan, David, et al.
Publicado: (2023)

RETINAL VASCULITIS OR VASCULAR OCCLUSION AFTER BROLUCIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Systematic Review of Real-World Evidence
por: Wykoff, Charles C., et al.
Publicado: (2023)

Home Monitoring of Age-Related Macular Degeneration: Utility of the ForeseeHome Device for Detection of Neovascularization
por: Yu, Hannah J., et al.
Publicado: (2020)

RETINAL FLUID AND THICKNESS AS MEASURES OF DISEASE ACTIVITY IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
por: Kaiser, Peter K., et al.
Publicado: (2021)

Clinical experience with fixed bimonthly aflibercept dosing in treatment-experienced patients with neovascular age-related macular degeneration
por: Khanani, Arshad M
Publicado: (2015)

Quantitative multimodal imaging of extensive macular atrophy with pseudodrusen and geographic atrophy with diffuse trickling pattern
por: Antropoli, Alessio, et al.
Publicado: (2023)

CLINICOPATHOLOGIC CORRELATION OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
por: Li, Miaoling, et al.
Publicado: (2019)

IMPACT OF RETINAL FLUID-FREE MONTHS ON OUTCOMES IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Treatment Agnostic Analysis of the HAWK and HARRIER Studies
por: Eichenbaum, David, et al.
Publicado: (2023)

Pharmacokinetics of the Port Delivery System with Ranibizumab in the Ladder Phase 2 Trial for Neovascular Age-Related Macular Degeneration
por: Wykoff, Charles C., et al.
Publicado: (2022)

Macular Sensitivity Endpoints in Geographic Atrophy: Exploratory Analysis of Chroma and Spectri Clinical Trials
por: Chang, Dolly S., et al.
Publicado: (2023)

Determinants of Quality of Life in Geographic Atrophy Secondary to Age-Related Macular Degeneration
por: Künzel, Sandrine H., et al.
Publicado: (2020)

Retinal Vessel Density in Age-Related Macular Degeneration Patients with Geographic Atrophy
por: Hong, Suji, et al.
Publicado: (2022)

RANTES (CCL5) in Patients With Geographic Atrophy Age-Related Macular Degeneration
por: Fonteh, Cheryl N., et al.
Publicado: (2023)

Geographic Atrophy in Age-Related Macular Degeneration: A Tale of Two Stages
por: Keenan, Tiarnan D.L.
Publicado: (2023)

The Role of Inflammation in Age-Related Macular Degeneration—Therapeutic Landscapes in Geographic Atrophy
por: Borchert, Grace A., et al.
Publicado: (2023)

Phase 1 Study of THR-687, a Novel, Highly Potent Integrin Antagonist for the Treatment of Diabetic Macular Edema
por: Khanani, Arshad M., et al.
Publicado: (2021)

Using Geographic Information for Disease Surveillance at Mass Gatherings
por: Blatt, Amy J.
Publicado: (2014)

THE PATHOPHYSIOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION AND THE COMPLEMENT PATHWAY AS A THERAPEUTIC TARGET
por: Boyer, David S., et al.
Publicado: (2017)

Choriocapillaris changes in dry age-related macular degeneration and geographic atrophy: a review
por: Arya, Malvika, et al.
Publicado: (2018)

HISTOLOGY OF GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION: A Multilayer Approach
por: Li, Miaoling, et al.
Publicado: (2018)

Prognostic value of intermediate age-related macular degeneration phenotypes for geographic atrophy progression
por: Thiele, Sarah, et al.
Publicado: (2021)

Prevalence of Geographic Atrophy in Advanced Age-Related Macular Degeneration (AMD) in Daily Practice
por: Abdin, Alaa Din, et al.
Publicado: (2023)

Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map
por: Khanani, Arshad M., et al.
Publicado: (2021)

Cooling Anesthesia for Intravitreal Injection: Results of the Prospective Open-Label, Dose-Ranging COOL-1 Trial
por: Chao, Daniel L, et al.
Publicado: (2021)

Prevalence and Genetic Characteristics of Geographic Atrophy among Elderly Japanese with Age-Related Macular Degeneration
por: Sakurada, Yoichi, et al.
Publicado: (2016)

Clinical and Genetic Factors Associated with Progression of Geographic Atrophy Lesions in Age-Related Macular Degeneration
por: Grassmann, Felix, et al.
Publicado: (2015)

Systemic expression of Alu RNA in patients with geographic atrophy secondary to age-related macular degeneration
por: Yoshida, Hiroyuki, et al.
Publicado: (2019)

Plasma biomarkers of the amyloid pathway are associated with geographic atrophy secondary to age-related macular degeneration
por: Lashkari, Kameran, et al.
Publicado: (2020)

Healthcare Resource Utilization and Costs in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
por: Kim, Ashley, et al.
Publicado: (2021)

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy
por: Khanani, Arshad M., et al.
Publicado: (2022)

Macular Telangiectasia Type 2: A Comprehensive Review
por: Kedarisetti, Kiran Chandra, et al.
Publicado: (2022)

TENAYA and LUCERNE: Rationale and Design for the Phase 3 Clinical Trials of Faricimab for Neovascular Age-Related Macular Degeneration
por: Khanani, Arshad M., et al.
Publicado: (2021)

Emerging Therapies in Neovascular Age-Related Macular Degeneration in 2020
por: Samanta, Anindya, et al.
Publicado: (2020)

Macular thickness amplitude changes when switching from discontinuous to continuous therapy for diabetic macular oedema
por: Schechet, Sidney A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lgj5js5gs38bf3e61oaefrig2b